About immunocore holdings - IMCR
Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. Its lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.
IMCR At a Glance
Immunocore Holdings Plc
92 Park Drive
Abingdon, Oxfordshire OX14 4RY
| Phone | 44-1235-438600 | Revenue | 400.95M | |
| Industry | Biotechnology | Net Income | -35,596,991.63 | |
| Sector | Health Technology | 2025 Sales Growth | 29.2% | |
| Fiscal Year-end | 12 / 2026 | Employees | 524 | |
| View SEC Filings |
IMCR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.358 |
| Price to Book Ratio | 4.644 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -31.291 |
| Enterprise Value to Sales | 3.292 |
| Total Debt to Enterprise Value | 0.331 |
IMCR Efficiency
| Revenue/Employee | 765,173.255 |
| Income Per Employee | -67,933.19 |
| Receivables Turnover | 3.965 |
| Total Asset Turnover | 0.386 |
IMCR Liquidity
| Current Ratio | 4.04 |
| Quick Ratio | 4.013 |
| Cash Ratio | 3.503 |
IMCR Profitability
| Gross Margin | 97.912 |
| Operating Margin | -11.338 |
| Pretax Margin | -4.775 |
| Net Margin | -8.878 |
| Return on Assets | -3.428 |
| Return on Equity | -9.598 |
| Return on Total Capital | -4.353 |
| Return on Invested Capital | -4.429 |
IMCR Capital Structure
| Total Debt to Total Equity | 114.606 |
| Total Debt to Total Capital | 53.403 |
| Total Debt to Total Assets | 40.916 |
| Long-Term Debt to Equity | 114.08 |
| Long-Term Debt to Total Capital | 53.158 |